Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna says COVID-19 vaccine supply outside United States to slow down

07/27/2021 | 01:02pm EDT
FILE PHOTO: Test tubes are seen in front of a displayed Moderna logo in this illustration

SEOUL (Reuters) - Moderna said on Tuesday its COVID-19 vaccine manufacturing partners outside the United States are facing delays due to laboratory testing operations that have occurred in the past few days, slowing the supply of the shot to these markets.

The vaccine maker's comments come after South Korean health officials said earlier in the day that Moderna has delayed its late-July vaccine shipment schedule for the country to August due to supply problems.

"We are currently not reserving safety stock to allow vaccines to be delivered faster, which means that we do not have stock in storage to smooth these types of shortfalls or delays," a Moderna spokesperson said. The issue was now resolved, but the delay will lead to a short-term adjustment in the upcoming 2-4 weeks, the spokesperson said.

The shipment delay comes as the South Korean government expands its inoculation campaign to people in their 50s and workers in its vital computer chip and electronic sector.

The disruption has forced authorities to switch to the Pfizer vaccine for some vaccinations.

Moderna and its manufacturing partners are working to minimize this shortfall across all impacted nations, the company said without naming the affected countries and the severity of the issue.

The supply issue is linked to the vaccine manufacturing process involving Swiss contract drugmaker Lonza and a Spain-based company, which does bottling work for the Moderna vaccine, said Jung Eun-young, head of the vaccine procurement team.

"This means the production-related issue does not only affect South Korea. Rather it is a common problem for countries that receive the volume from the manufacturing site," Jung said in a news conference.

She did not name the Spanish firm, but contract drugmaker Rovi bottles, or "fills and finishes," Moderna vaccines for markets other than the United States.

Contract drugmaker Lonza said questions on COVID-19 vaccine should be directed to Moderna. Rovi was not available for comment.

South Korea has a contract for 40 million doses of the Moderna vaccine, of which about 1.1 million have already arrived.

The country is battling a fourth wave of infections linked to the spread of the more contagious Delta variant and public complacency that has seen daily cases breach the 1,000 mark for the first time since December.

Authorities reported 1,365 new coronavirus cases for Monday.

South Korean officials said the Moderna vaccines scheduled to arrive in August remained on schedule, adding that a detailed shipment plan would be made public once finalised.

Shares of the drugmaker fell 3.7% to $323.5 in morning trade.

(Reporting by Sangmi Cha; Additional reporting by Inti Landauro in Madrid, Brenna Hughes Neghaiwi in Zurich and Manas Mishra in Bengaluru; Editing by Miyoung Kim, Lincoln Feast, Joe Bavier and Arun Koyyur)

By Sangmi Cha

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
LABORATORIOS FARMACEUTICOS ROVI, S.A. 0.00% 55.1 Delayed Quote.45.38%
LONZA GROUP AG -3.88% 693.6 Delayed Quote.26.86%
MODERNA, INC. -6.02% 384.21 Delayed Quote.267.77%
All news about LONZA GROUP AG
09/24LONZA : To Manufacture Allarity Therapeutics' Kidney Cancer Candidate Dovitinib
09/23LONZA : Stifel Lifts Price Target on Lonza Group, Maintains Hold Recommendation
09/23Allarity Therapeutics and Lonza Collaborates to Manufacture Dovitinib, a Renal Cell Car..
09/22LONZA : to Invest in Expanding Drug Product Development Network in Switzerland
09/22LONZA : Invests to Expand Drug Product Development and Manufacturing Services in Switzerla..
09/21LONZA : Triumvira Begins Human Trials for T-Cell Cancer Therapy
09/21Lonza and Triumvira Immunologics Announces First Patient with HER2-overexpressing Cance..
09/13LONZA : Swiss Parliament Excluded from Federal Council's Vaccine Production Talks With Lon..
08/26GLOBAL MARKETS LIVE : UMG, Delta Air Lines, Shiseido, Qantas, Lonza...
08/26LONZA : CFO to Move to Another Company; Novartis Executive to Take Over
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Sales 2021 5 151 M 5 541 M 5 541 M
Net income 2021 750 M 807 M 807 M
Net cash 2021 314 M 338 M 338 M
P/E ratio 2021 69,2x
Yield 2021 0,44%
Capitalization 51 523 M 55 527 M 55 426 M
EV / Sales 2021 9,94x
EV / Sales 2022 8,77x
Nbr of Employees 14 405
Free-Float 99,7%
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 693,60 CHF
Average target price 765,21 CHF
Spread / Average Target 10,3%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG26.86%57 923
MODERNA, INC.267.77%165 027
CELLTRION, INC.-26.60%31 003
SEAGEN INC.-7.85%29 566